Biodexa Pharmaceuticals Plc
BDRX
$7.51
-$0.26-3.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 6.07% | -49.59% | |||
| Gross Profit | -6.07% | 49.59% | |||
| SG&A Expenses | 6.06% | 32.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -5.88% | 14.57% | |||
| Total Operating Expenses | 6.06% | -20.63% | |||
| Operating Income | -6.06% | 20.63% | |||
| Income Before Tax | -6.06% | -53.39% | |||
| Income Tax Expenses | -6.06% | -29.88% | |||
| Earnings from Continuing Operations | -6.06% | -54.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.06% | -54.61% | |||
| EBIT | -6.06% | 20.63% | |||
| EBITDA | -6.06% | 21.26% | |||
| EPS Basic | -6.06% | 59.46% | |||
| Normalized Basic EPS | -6.06% | 59.78% | |||
| EPS Diluted | -6.06% | 59.46% | |||
| Normalized Diluted EPS | -6.06% | 59.78% | |||
| Average Basic Shares Outstanding | 0.00% | 281.72% | |||
| Average Diluted Shares Outstanding | -- | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||